|
|
||||||||
The Rowett Research Institute, Bucksburn, Aberdeen AB21 9SB, Scotland, United Kingdom
Muscle wasting affects large numbers of people, but few
therapeutic approaches exist to treat and/or reverse this condition. The
2-adrenoceptor agonist clenbuterol produces a
muscle-specific protein anabolism in both normal and catabolic muscle
and has been used to limit muscle wasting in humans. Because
clenbuterol appears to interact with or mimic innervation, its effect
on the expression of the neurotrophic agents insulin-like growth factor (IGF)-II and H19 and their putative pathways was examined in normal rat
plantaris muscle. The results showed that the well-documented early
effects of clenbuterol on protein metabolism were preceded by elevated
levels of IGF-II and H19 transcripts together with increased
phosphorylation of eukaryotic initiation factor (eIF)4E binding
protein-1 (4E-BP1) and p70S6k. By 3 days, transcript levels
for IGF-II and H19 and 4E-BP1 and p70S6k phosphorylation
had returned to control values. These novel findings indicate that
clenbuterol-induced muscle anabolism is potentially mediated, at least
in part, by an IGF-II-induced activation of 4E-BP1 and
p70S6k.
hypertrophy;
-agonist; growth factor; protein translation; insulin-like growth factor II; eukaryotic initiation factor 4E binding
protein-1
This article has been cited by other articles:
![]() |
M. Sandri Signaling in Muscle Atrophy and Hypertrophy Physiology, June 1, 2008; 23(3): 160 - 170. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. S. Lynch and J. G. Ryall Role of {beta}-Adrenoceptor Signaling in Skeletal Muscle: Implications for Muscle Wasting and Disease Physiol Rev, April 1, 2008; 88(2): 729 - 767. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. J. McCarthy and K. A. Esser Counterpoint: Satellite cell addition is not obligatory for skeletal muscle hypertrophy J Appl Physiol, September 1, 2007; 103(3): 1100 - 1102. [Full Text] [PDF] |
||||
![]() |
W. O. Kline, F. J. Panaro, H. Yang, and S. C. Bodine Rapamycin inhibits the growth and muscle-sparing effects of clenbuterol J Appl Physiol, February 1, 2007; 102(2): 740 - 747. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Pellegrino, G. D'Antona, S. Bortolotto, F. Boschi, O. Pastoris, R. Bottinelli, B. Polla, and C. Reggiani Clenbuterol antagonizes glucocorticoid-induced atrophy and fibre type transformation in mice Exp Physiol, January 1, 2004; 89(1): 89 - 100. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |